Thiazolidinediones: a review of their benefits and risks. (Review Article).

ABSTRACT

Several new drugs have become available for the treatment of type 2 diabetes mellitus in the past few years, and among them the thiazolidinediones are probably the most promising and interesting. Their mechanism of action involves a reduction in insulin resistance while simultaneously improving some of the independent risk factors for cardiovascular disease frequently found in patients with type 2 diabetes mellitus. On the other hand, while they might have many advantages over the other available antihyperglycemic agents, there are still some concerns about their long-term safety. Consequently, while awaiting the results of the planned long-term cardiovascular outcome studies, which will help establish their true benefits and risks, physicians must remain skeptical about these drugs and consider not only their claimed advantages, but also their not-so-well-publicized risks. This article summarizes the known and/or presumed beneficial and toxic effects of these drugs.

**********

IT IS WELL ACCEPTED that the most important reason to treat type 2 diabetes mellitus aggressively is to prevent its chronic complications, both microvascular and macrovascular. It is also well known that the plasma glucose levels are causally and directly related to the microvascular complications (retinopathy, nephropathy, and neuropathy), and that the treatment of hyperglycemia, aimed at obtaining near-normoglycemia, prevents (or at least slows down) the progression of these complications, independent of the glucose-lowering agent used. (1-3)

Although these microvascular complications cause significant morbidity and cost, it is the macrovascular complications (coronary artery disease, cerebrovascular disease and peripheral vascular disease) that cause most of the excess mortality in patients with type 2 diabetes mellitus when compared with the rest of the population. The macrovascular complications are also responsible for a significant amount of morbidity and cost. (4-6) Moreover, the prevention of these macrovascular complications, particularly coronary artery disease, is not as simple as prevention of the microvascular complications. Although some evidence suggests that strict glycemic control does have a beneficial effect in terms of reduction of cardiovascular events, this benefit seems to be small. (3)

Consequently, to date, the prevention of the macrovascular complications in patients with type 2 diabetes mellitus is based on an aggressive approach to the modifiable, traditional risk factors for cardiovascular disease frequently present in these patients (ie, dyslipidemia, obesity, hypertension, and smoking). Furthermore, although several other potentially independent risk factors for the development of cardiovascular disease in these patients have recently been identified--eg, Lp(a) lipoprotein, homocysteine, plasminogen activator inhibitor (PAI-1), fibrinogen, C-reactive protein, microalbuminuria, and others--we have had few, if any, means to modify them.

Fortunately, in the past few years, the Food and Drug Administration (FDA) has approved several new drugs for the treatment of hyperglycemia in patients with type 2 diabetes mellitus. The most promising of these are the thiazolidinediones (TZDs), since evidence suggests that they might have a direct beneficial effect on several of these cardiovascular risk factors, traditional and novel, independent of their hypoglycemic effects. In this review, we summarize the accumulated scientific evidence to date regarding these therapeutic agents (Table). For logical reasons, we only use human studies for evidence when discussing their potential benefits, but we include both human and animal studies when reviewing their potential toxicity.

THIAZOLIDINEDIONES

The TZDs are a new class of oral hypoglycemic agent. Currently, the only 2 drugs of this class on the market in the United States are rosiglitazone and pioglitazone. There is also clinical experience with a third TZD, troglitazone, which was withdrawn from the market in 2000 because of its hepatotoxicity. Several other drugs belonging to this class are currently in different stages of preclinical and clinical development in the drug industry. (7,8)

Mechanism of Action

The hypoglycemic effect of the TZDs is related to their ability to increase insulin sensitivity and, consequently, increase peripheral glucose utilization. Although the exact mechanism of action is not completely understood, the most widely-accepted hypothesis is that their effect on insulin sensitivity is related to their well-known ability to bind and activate the nuclear peroxisomal proliferator-activated receptors-gamma (PPAR-[gamma]). These receptors, which are abundant in adipocytes and are also present (to a lesser extent) in myocytes and other tissues, stimulate the expression of a number of genes that encode proteins involved in the metabolism of glucose and lipids. Their main biologic effect in adipose tissue, besides promoting the differentiation of pre-adipocytes into adipocytes, is to increase the uptake of fatty acids and lipogenesis. This "fatty-acid steal" in turn stimulates the nonoxidative metabolism of glucose in muscle and suppresses hepatic gluconeogenesis. (7,8)

BENEFITS

Glycemic Effects

In this manuscript, we do not review the glycemic effects of these drugs, since they have been recently and extensively reviewed elsewhere. However, the blood-glucose-lowering effect of the currently available TZDs is similar; all of the TZDs lower the hemoglobin [A.sub.1c] (Hb[A.sub.1c]) level by approximately 0.5% to 1.5%, depending on the circumstances in which they are being used and/or studied. (9,10)

Insulin Resistance/Hyperinsulinemia

Besides lowering plasma glucose, the TZDs also lower the circulating insulin levels and/or the insulin dose required to achieve appropriate glycemic control in patients with type 2 diabetes mellitus. This reduction in the degree of insulin resistance causes an increase in peripheral glucose uptake, and also, under certain circumstances, reduces hepatic basalglucose production. (11-13)

Dyslipidemia

Most of the studies with TZDs have shown that these drugs increase the high-density lipoprotein (HDL) levels by approximately 5% to 15%, though it seems that this increase is only due to an increase in its HDL3 subfraction. (9,11,14-16) Their effects on triglyceride levels are more variable and controversial. Most (but not all) of the studies using troglitazone and pioglitazone have shown a trend toward a reduction of approximately 10% to 20% in the plasma triglyceride levels; rosiglitazone does not seem to share this triglyceride-lowering effect. (9,11,12) In general, TZDs lower levels of circulating free fatty acids, and this is thought to be one of the most important mechanisms contributing to their ability to lower insulin resistance. (12,17,18)

Hypertension

Several studies using troglitazone have shown reductions in blood pressure in hypertensive as well as normotensive patients with type 2 diabetes mellitus. These reductions have ranged from as little as 3 mm Hg to as high as 9 mm Hg in mean arterial pressure. Other studies, however, have not been able to reproduce these findings. (19-24)

Microalbuminuria

Studies using troglitazone and rosiglitazone in patients with type 2 diabetes mellitus and microalbuminuria have shown reductions in the urinary microalbumin-to-creatinine ratio of up to 60%, independent of their glucose-lowering and/or blood-pressure-lowering effects. (25-29)

Vascular Endothelium 

In humans, troglitazone seems to have a potent inhibitory effect on the progression of early atherosclerotic lesions at 3 and 6 months after beginning therapy, as shown by ultrasound technique (B-mode) evaluating the thickness of the intimal and medial layers of the common carotid artery walls. (30) Moreover, troglitazone has shown the ability to inhibit coronary restenosis in patients with type 2 diabetes mellitus who have had coronary angioplasty with the use of stents. (31) Evidence shows that the TZDs increase muscular blood flow through a not-well-understood vasodilatation process (32); however, other investigators have not been able to reproduce this vasodilatory effect. (33)

Thrombogenic Factors/Procoagulant State

The TZDs seem to cause a reduction in the blood levels of plasminogen activator inhibitor-1 (PAI-1) and fibrinogen, which are frequently found to be elevated in patients with type 2 diabetes mellitus and are thought to contribute to their increased risk for cardiovascular disease. All investigators, however, have not been able to reproduce these effects. (24,34-36)

Fat Tissue Distribution

Several studies using troglitazone have shown that it selectively reduces intra-abdominal (visceral) fat while increasing total body fat, mostly by means of increasing peripheral subcutaneous fat. (37-39) This quality is interesting and potentially important, since it has recently been shown that the intra-abdominal fat is the main fat tissue in the body responsible for the insulin resistance observed in obesity. Reductions in this intra-abdominal fat tissue by means of caloric restriction or exercise, are known to lower insulin resistance and other manifestations of the metabolic syndrome. (40,41)

Pancreatic Beta Cells/Insulin Secretion

Growing evidence in patients with impaired glucose tolerance and type 2 diabetes seems to indicate that the TZDs improve the secretory capacity of the pancreatic [beta] cells in the short term as well as in the long term. (42-44) The mechanism responsible for this effect is not well understood; nevertheless, a recent study showed that PPAR-[gamma] receptors are highly expressed in human islet endocrine cells. (45)

Bone Turnover

One study suggests that the TZDs might decrease bone turnover independent of their effects on glucose metabolism, as evidenced by a decrease in bone-resorption markers in patients with type 2 diabetes mellitus. However, this finding needs to be validated by other investigators; moreover, whether this effect will translate into an increase in bone mineral density and a decrease in fracture risk in patients with type 2 diabetes mellitus remains to be seen. (46)

Other Beneficial Effects

Polycystic Ovary Syndrome. Since the TZDs lower insulin resistance, they would be expected to be of benefit in the treatment of other conditions associated with insulin resistance. They have been studied in patients with polycystic ovary syndrome and have shown the capacity to improve the metabolic and reproductive abnormalities associated with this syndrome, helping, among other things, to induce ovulation. (47,48)

Severe Insulin-Resistance Syndromes. The TZDs have been found effective in the treatment of Werner's syndrome, several genetic and/or autoimmune lipodystrophy syndromes, as well as the poorly-understood HIV-associated lipodystrophy-dysmetabolic syndrome. (49-51)

Neoplasms. Several in vitro studies and a few in vivo animal studies suggest that the TZDs might have antiproliferative effects in colon, prostate, breast, lung, and gastric cancer cell lines, as well as inhibitory effects on estrogen biosynthesis in breast adipose tissue. (52-61) However, the only evidence in humans for a potential therapeutic role of the TZDs in the treatment of cancers comes from a small, uncontrolled study (involving only 3 patients), which showed that TZDs can induce solid/terminal tumor differentiation in patients with malignant liposarcoma. Whether this will translate into any clinical benefit remains to be seen. (62)

RISKS

In general, the TZDs are well tolerated with few side effects; nonetheless, potential adverse effects deserve some attention.

Hepatic Toxicity

The hepatotoxicity of troglitazone is well known and resulted in its withdrawal from the US market in early 2000; it has been reported to cause reversible abnormalities in liver function tests in 2% of patients, and severe, irreversible liver failure in approximately 1 in 50,000 patiens. (51,63-70) The other TZDs currently available in the United States, rosiglitazone and pioglitazone, do not seem to share this problem. During premarketing and postmarketing clinical trials, the incidence of abnormal liver enzymes in patients treated with these drugs has been the same as that for the placebo/control groups. Only 2 cases of severe liver disease that developed in patients receiving rosiglitazone have been published; both were reversible and in both cases a causal association with rosiglitazone is not clear, since there were several confounding factors. (71-73) Nonetheless, until more longterm experience with these drugs is available, we must follow FDA recommendations for monitoring liver enzymes: check bimonthl y for the first year that the drugs are prescribed, and periodically thereafter. (74,75)

Lipid Effects

The TZDs increase low-density lipoprotein (LDL) levels by approximately 5% to 15%. Although this increase seems to be due to an increase in the size and reduction in the density of the lipoprotein particles by making them larger and fulffy, and therefore presumably less atherogenic, this remains a reason for concern. (9,14) Additionally, evidence shows that troglitazone might increase the plasma levels of Lp(a) lipoprotein; however the magnitude and significance of this increment are not clear. (76,77)

Hematologic Effects

In general, during clinical studies, the TZDs have caused reductions of 2% to 4% in hematocrit level, and decreases of up to 1 g/dL in hemoglobin level; similarly, mild decreases in white blood cell counts and platelet counts have been noted. (9,11,63,74,75,78) Although the exact cause of these decreases is not known, the effects have been attributed to a hemodilutional effect from an increase in plasma volume. A toxic effect on the bone marrow cannot be completely ruled out, however, since bone marrow hypocellularity and increased bone marrow fat have been observed in animals. (78)

Fluid Retention/Edema

Edema (most frequently only lower-extremity edema) has been reported in approximately 5% of patients treated with TZDs, and in up to 15% of patients when used in combination with insulin during clinical trials. (9,63,74,75) This problem may be severe enough to warrant discontinuance of these agents. Furthermore, pulmonary edema has been documented in the literature. (79) Although the cause for this edema is not well understood, it may be related to the 6% to 8% increase in plasma volume that has been observed in clinical studies. (63)

Weight Gain/Obesity

As with any other hypoglycemic drug, with the exception of the biguanides, patients treated with TZDs gain weight. This is probably due to several factors, including the obvious increase in plasma volume that happens when correcting the state of chronic dehydration in which patients with chronic hyperglycemia live, and cessation of the caloric loss through the urine (glucosuria). In the case of the TZDs, it is probably also due to the increase in the total body fat that is known to happen in patients treated with these drugs. (8,37-39) During clinical trials, this weight gain has been reported to be from 2 to 6 kg during the first 6 months to 1 year of treatment, depending upon the circumstances in which the drugs are used. (9,66-68) In clinical practice, however, it is not rare to find patients who gain a much greater amount of weight, occasionally more than 20 kg, making it necessary to discontinue these medications. (80) Unfortunately, thus far there is no way to predict which patient will gain excessive w eight. We also do not know if this increase in total body fat and weight is reversible, or if it can result in a "TZD-resistant state" due to an increase in insulin resistance that hypothetically could happen after a critical threshold in total-body-fat mass is reached. (8,17)

Cardiac Toxicity

Multiple studies in animals (mice, rats, dogs, and monkeys) have shown that some of the TZDs can cause cardiac hypertrophy, though this effect has not been shown thus far in human studies. (20,63,74,75,78,81) Nonetheless, because TZDs may cause an increase in plasma volume, they are contraindicated in patients with New York Heart Association Class III and Class IV heart failure. There have been reports of pulmonary edema developing after the addition of a TZD to the therapeutic regimen of patients with type 2 diabetes mellitus. (79)

Neoplastic Potential

Several studies, mostly in vitro, suggest that the TZDs might have antiproliferative effects on certain types of cancer cells; however, other studies, mostly in vivo animal studies, show that the TZDs may induce the formation of lipomas, benign and/or malignant urinary bladder (transitional cell) tumors, vascular tumors (hemangiomas and hemangiosarcomas), and the growth of uterine leiomyomas. (74,75,82,83) Furthermore, under certain circumstances, the TZDs can promote the development of colorectal cancer and/or polyps; because of this risk, it has been suggested that TZDs should not be prescribed to patients who are known to be at high risk for development of colon polyps (eg, those patients belonging to a family with adenomatous polyposis coli). (8,84,85) Some of these tumors were observed only after long-term administration of the TZD. (82)

Cost

Cost is also an important issue and a significant disadvantage of the TZDs. The currently available TZDs have been priced significantly higher than any of the other oral hypolycemic agents, with prices up to and above $150 for a 1-month supply of the higher doses.

CONCLUSION

When compared with the remainder of the drugs currently available for the treatment of hyperglycemia in patients with type 2 diabetes mellitus, the TZDs offer the advantage of simultaneously improving several of the independent cardiovascular risk factors commonly associated with the insulin-resistance syndrome. It would be expected then, at least hypothetically, that the TZDs would help prevent and/or slow down the progression of arteriosclerosis and cardiovascular disease in patients with type 2 diabetes mellitus. Because of their potential for adverse effects, unclear long-term safety, the not-so-well-established long-term benefits, and the considerable expense, however, we must be prudent with their use, remain skeptical, and wait for the results of the long-term cardiovascular outcome studies that are currently underway to help establish the true long-term safety and effectiveness of these drugs in preventing the macrovascular complications in patients with type 2 diabetes mellitus.

TABLE

Porven and Potential Benefits and Risks of the Thiazolidinedlones


Benefits

  Improved glycemic control
  Lower insulin resistance/insulin levels
  Increased HDL levels
  Lower triglyceride levels
  Fat redistribution/decreased visceral fat
  Lower blood pressure
  Decreased microalbuminuria
  Improved pancreatic [beta]-cell function
  Improved endothelial function
  Lower PAI-1 levels
  Lower fibrinogen levels
  Induction of valuation in PCOS
  Less bone turnover
  Treatment for neoplasms

Risks

  Hepatotoxicity/potential for liver failure
  Increased LDL levels
  Weight gain/increased total body fat
  Edema/fluid retention
  Pulmonary edema
  Increased Lp(a) lipoprotein levels
  Bone marrow toxicity *
  Cardiac toxicity *
  Induction of neoplasms *

* Thus far, only in vitro and/or in vivo animal studies have reported
these risks.

HDL = High-density lipoprotein, LDL = low-density lipoprotein, PAI-1 =
plasminogen activator inhibitor-1, PCOS = polycystic ovary syndrome.

References

(1.) The Diabetes control and complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl Med 1993; 329:977-986

(2.) ohkubo Y, Kishikawa H, Araki E, et al: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103-117

(3.) UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853

(4.) Kannel WB, McGee DL: Diabetes and cardiovascular disease risk factors: the Framingham Study. circulation 1979; 59:8-13

(5.) Rubin RJ, Altman WM, Mendelson DN: Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 1994; 78:809A-809F

(6.) Donnelly R, Emslie-Smith AM, Gardner ID, et al: Vascular complications of diabetes. BMJ 2000; 320:1062-1066

(7.) Day C: Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16:179-192

(8.) Schoonjans K, Auwerx J: Thiazolidinediones: an update. Lancet 2000; 355:1008-1010

(9.) DeFronzo R: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131:281-303

(10.) Defronzo R: Pharmacologic therapy for type 2 diabetes mellitus (Letter). Ann Intern Med 2000; 133:73-74

(11.) Kumar S, Boulton AJM, Beck-Nielsen H, et al: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39:701-709

(12.) Maggs DG, Buchanan TA, Burant CF, et al: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. Ann Intern Med 1998; 128:176-185

(13.) Inzucchi SE, Maggs DG, Spollett GR, et al: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338:867-872

(14.) Tack CJ, Smits P, Demacker PNM, et al: Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998; 21:796-799

(15.) Nozue T, Michishita I, Minagawa F, et al: Troglitazone directly increases HDL cholesterol levels. Diabetes Care 1999; 22:355-356

(16.) Ovalle F, Bell DSH: The effect of thiazolidinediones on HDL subfractions. Diabetes 2000; 49 (suppl 1):A269

(17.) Scheen AJ, Lefebvre PJ: Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999; 22:1568-1577

(18.) Reginato MJ, Lazar MA: Mechanisms by which thiazolidinediones enhance insulin action. Trends Endocrinol Metab 1999;10:9-13

(19.) Ogihara T, Rakugi H, Ikegami H, et al: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8:316-320

(20.) Ghazzi MN, Perez JE, Antonucci TK, et al: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. the Troglitazone Study Group. Diabetes 1997; 46:433-439

(21.) Sung BH, Izzo JL, Dandona P, et al: Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999; 34:83-88

(22.) Iwamoto Y, Kosaka K, Kuzuya T, et al: Effects of troglitazone, a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19:151-156

(23.) Bakris GL, Dole JF, Porter LE, et al: Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus. Diabetes 2000; 49(suppl 1):A96

(24.) Sironi AM, Vichi S, Gastaldelli A, et al: Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther 1997; 62:194-202

(25.) Claudi T, Starkie M, Frith L, et al: Troglitazone improves cardiovascular risk profile compared with glibencamide. Diabet Med 1997; 14(suppl 4):530

(26.) Imano E, Kanda T, Nakatani Y, et al: Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21:2135-2139

(27.) Miura Y, Kato Y, Yamamoto N, et al: Troglitazone improves diabetic nephropathy in patients with type 2 diabetes. Diabetes, 2000; 49(suppl 1):A19-A20

(28.) Bakris G, Weston WM, Rappaport EB, et al: Rosiglitazone produces long-term reductions in urinary albumin excretion in type 2 diabetes. Diabetologia 1999; 42(suppl 1):A230

(29.) Freed MI, Weston WM, Viberti C: Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. Diabetologia 1999; 42(suppl 1):A230

(30.) Minamikawa J, Tanaka S, Yamauchi M, et al: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83:1818-1820

(31.) Tagaki T, Yoshida JK, Akasaka T, et al: Troglitazone reduces intimal hyperplasia after coronary stent implantation in patients with type 2 diabetes mellitus: a serial intravascular ultrasound study (Abstract 886-2). J Am Coll Cardiol 1999; 33:100A

(32.) Fujishima S, Ohya Y, Nakamura Y, et al: Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am J Hyperlens 1998; 11:1134-1137

(33.) Tack CJJ, Ong MKE, Lutterman JA, et al: Insulin induced vasodilatation and endothelial function in obesity/insulin resistance. effects of troglitazone. Diabetologia 1998; 41:569-576

(34.) Kubo K: Effects of troglitazone on coagulation-fibrinolysis abnormalities in patients with type II diabetes mellitus. Curr Ther Res Clin Exp 1998; 59:537-544

(35.) Fonseca VA, Reynolds T, Hemphill D, et al: Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Comp 1998; 4: 181-186

(36.) Ehrmann DA, Schneider DJ, Sobel BE, et al: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2108-2116

(37.) Kelly IE, Han TS, Walsh K, et a1: Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22:288-293

(38.) Mori Y, Murakawa Y, Okada K, et al: Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999; 22:908-912

(39.) Akasawa S, Sun F, Ito M, et al: Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23:1067-1071

(40.) Brunzell JD, Hokanson JE: Dyslipidemia of central obesity and insulin resistnnce. Diabetes Care 1999; 22(suppl 3):C10-C13

(41.) Bonora E: Relationship between regional fat distribution and insulin resistance. Int J Obes 2000; 24(suppl 2) S32-S35

(42.) Cavaghan MK, Ehrmann DA, Byrne MN, et al: Treatment with the oral antidiabetic agent troglitazone improves [beta]-cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100:530-537

(43.) Prigeon RL, Kahn SE, Porte D Jr: Effect of troglitazone on [beta]-cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 1998; 83:819-823

(44.) Ovalle F, Bell DSH: Thiazolidinedione induced recovery of pancreatic beta cell function. Diabetes 2000; 49(suppl 1):A120

(45.) Dubois M, Pattou F, Kerr-Conte J, et al: Expression of peroxisome proliferator-activated receptor gamma (PPARagamma) in normal human pancreatic islet cells. Diabetologia 2000; 43:1165-1169

(46.) Okazaki R, Miura M, Toriumi M, et al: Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocrinol J 1999; 46:795-801

(47.) Dunaif A, Scott D, Finegood D, et al: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299-3306

(48.) Ehrmann DA, Schneider DJ, Sobel BE, et al: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2108-2116

(49.) Izumino K, Sakamaki H, Ishibashi M, et al: Troglitazone ameliorates insulin resistance in patients with Werner's syndrome. J Clin Endocrinol Metab 1997; 82:2391-2395

(50.) Walli R, Michl GM, Muhlbayer D, et al: Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med (Berl) 2000; 199:253-262

(51.) Arioglu E, Duncan-Morin J, Sebring N, et al: Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133:263-274

(52.) Brockman JA, Gupta RA, Dubois RN: Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998; 115:1049-1055

(53.) Kitamura S, Miyazaki Y, Shinomura Y, et al: Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999; 90:75-80

(54.) Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4:1004-1005

(55.) Kubota T, Koshizuka K, Williamson EA, et al: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in-vitro and in-vivo. Cancer Res 1998; 58:3344-3352

(56.) Elstner E, Muller C, Koshizucka K, et al: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proe Natl Acad Sci USA 1998; 95:8806-8811

(57.) Yee LD, Sabourin CL, Liu L, et al: Peroxisome proliferator-activated receptor gamma activation in human breast cancer. Int J Oncol 1999; 15:967-973

(58.) Mehta KG, Wiliamson E, Patel MK, et al: A ligand peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000; 92:418-423

(59.) Tsubouchi Y, Sano H, Kawahito Y, et al: Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biocem Biophys Res Commun 2000; 270:400-405

(60.) Takahashi N, Okumura T, Motomura W, et al: Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999; 455:135-139

(61.) Rubin GL, Zhao Y, Kalus AM, et al: Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000; 60:1604-1608

(62.) Demetri GD, Fletcher CD, Mueller E, et al: Induction of solid tumor differentiation by peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999; 96:3951-3956

(63.) Rezulin (troglitazone) [package insert]. Morris Plains, NJ, Parke-Davis, Division of Warner Lambert Co, 1999

(64.) Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338:916-917

(65.) Misbin RI: Troglitazone-associated hepatic failure. Ann Intern Med 1999; 130:330

(66.) Gitlin N, Julie NL, Spurr CL, et al: Two cases of severe clinical and histologic hepatic toxicity associated with troglitazone. Ann Intern Med 1998; 129:36-38

(67.) Neuschwander-Tetri BA, Isley WI, Oki JC, et al: Troglitazoneinduced failure leading to liver transplantation. Ann Intern 2 Med 1998; 129:38-41

(68.) Vella A, de Groen PC, Dinneon SF: Fatal hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129:1080

(69.) Bell DSH, Ovalle F: Late-onset troglitazone-induced hepatic dysfunction. Diabetes Care 2000; 23:128-429

(70.) Bailey CJ: The rise and fall of troglitazone. Diabet Med 2000; 17:414-415

(71.) Forman L, Dimmans DA, Diamond RH: Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000; 132:118-121

(72.) Al-Salman J, Arjomand H, Kemp DG, et al: Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med 2000; 132:121-124

(73.) Freid J, Everitt D, Boscia J: Rosiglitazone and hepatic failure. Ann Intern Med 2000; 132:164

(74.) Avandia (rosiglitazone) [package insert]. Philadelphia, Pa, SmithKline Beecham Co, 1999

(75.) Actos (pioglitazone) [package insert]. Lincolnshire, Ill, Takeda Pharmaceutical of America Inc, 2000

(76.) Matsumoto K, Miyake S, Yano M, et al: Increase of lipoprotein (a) with troglitazone. Lancet 1997; 350:1748-1749

(77.) Ovalle F, Bell DSH: Troglitazone's effect on lipoprotein (a) levels. Diabetes Care 1999; 22:859-860

(78.) Williams GD, Deldar A, Jordan WH, et al: Subchronic toxicity of the thiazolidinedione Tanahe-174 (LY282449), in the rat and dog. Diabetes 1993; 42:186A

(79.) Hirsch IB, Kelly J, Cooper S: Pulmonary edema associated with troglitazone therapy. Arch Intern Med 1999; 159:1811

(80.) Gorson DM: Significant weight gain with Rezulin therapy. Arch Intern Med 1999; 159:99

(81.) Breider MA, Gough AW, Haskins JR, et al: Troglitazoneinduced heart and adipose tissue cell proliferation in mice. Toxicol Pathol 1999; 27:545-552

(82.) Duddy SK, Parker RF, Bleavins MR, et al: P53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone. Toxicol Appl Pharmacol 1999; 156:106-112

(83.) Tsibris JC, Porter KB, Jazayeri A, et al: Human uterine leiomyomata express higher levels of peroxisome proliferator-activated receptor gamma, retinoid X receptor alpha, and all-trans retinoic acid than myometrium. Cancer Res 1999; 59:5737-5744

(84.) Lefebvre A, Chen I, Desreumaux P, et al: Activation of the peroxisome proliferator-acitivated receptor gamma promotes the development of colon tumors in C57BL/6J-APC-/+ mice. Nat Med 1998; 4:1053-1057

(85.) Saez E, Tontonoz P, Nelson MC, et al: Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998; 4:1058-1061

RELATED ARTICLE: KEY POINTS

* Thiazolidinediones are a new class of drugs available for the treatment of type 2 diabetes mellitus.

* Thiazolidinediones have the potential to reduce the development of cardiovascular disease.

* Thiazolidinediones have several side effects that need to be kept in mind when prescribing these drugs.

From the Department of Medicine, University of Alabama at Birmingham; and the Department of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico.

Reprint requests to Fernando Ovalle, MD, University of Alabama at Birmingham School of Medicine, Division of Endocrinology and Metabolism, 1808 7th Ave S, BDB 813, Birmingham, AL 35294.